Clinical trial
Olmesartan Medoxomil and Diabetic Nephropathy
NCT00362960 · Sankyo Pharma Gmbh, Industry · Completed
Key facts
| NCT number | NCT00362960 |
|---|---|
| Title | Olmesartan Medoxomil and Diabetic Nephropathy |
| Official title | Effect of Different Doses of Olmesartan Medoxomil Compared to Losartan on Proteinuria, Renal Function and Inflammatory Markers in Type 2 Diabetics With Nephropathy |
| Lead sponsor | Sankyo Pharma Gmbh, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus, Diabetic Nephropathy, Proteinuria, Renal Disease |
| Intervention type | Drug |
| Interventions | Olmesartan medoxomil, Losartan |
| Enrollment | 300 |
| Start date | May 1, 2003 |
| Completion | Sep 1, 2004 |
| First posted | Aug 15, 2006 |
| Last update posted | Oct 9, 2006 |
| Countries | Czechia, Estonia, Germany, Netherlands, Poland, Slovakia, Spain |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: